15.80
+0.14(+0.89%)
Currency In USD
| Previous Close | 15.66 |
| Open | 15.62 |
| Day High | 15.88 |
| Day Low | 14.8 |
| 52-Week High | 18.38 |
| 52-Week Low | 8.24 |
| Volume | 341,406 |
| Average Volume | 1.3M |
| Market Cap | 1.03B |
| PE | -4.21 |
| EPS | -3.75 |
| Moving Average 50 Days | 14.68 |
| Moving Average 200 Days | 12.6 |
| Change | 0.14 |
If you invested $1000 in Mineralys Therapeutics, Inc. (MLYS) since IPO date, it would be worth $856.83 as of May 30, 2025 at a share price of $15.8. Whereas If you bought $1000 worth of Mineralys Therapeutics, Inc. (MLYS) shares 1 year ago, it would be worth $1,272.14 as of May 30, 2025 at a share price of $15.8.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)
GlobeNewswire Inc.
May 24, 2025 8:30 AM GMT
– Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world setting – – Lorundrostat 50 mg dosed once daily
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection
GlobeNewswire Inc.
May 20, 2025 12:00 PM GMT
RADNOR, Pa., May 20, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
GlobeNewswire Inc.
May 07, 2025 12:00 PM GMT
RADNOR, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA